Exact Sciences price target raised to $73 from $70 at Scotiabank

Scotiabank raised the firm’s price target on Exact Sciences (EXAS) to $73 from $70 and keeps an Outperform rating on the shares. Exact’s Q4 was in line with the January 12 preannouncement, and the company ended FY24 slightly below initial guide provided last year, the analyst tells investors in a research note. The firm thinks Exact is strongly positioned competitively, based on clinical data presented so far, as well as its extensive commercial channels leveraging ExactNexus.